News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
265,108 Results
Type
Article (13770)
Company Profile (102)
Press Release (251236)
Section
Business (88062)
Career Advice (467)
Deals (15345)
Drug Delivery (67)
Drug Development (36605)
Employer Resources (49)
FDA (6291)
Job Trends (6208)
News (150240)
Policy (14025)
Tag
2024 BioCapital Digital (8)
2024 BioForest Digital (3)
2024 BioForest Standard (1)
2024 BioMidwest Digital (3)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (3)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (7)
2024 Biotech Beach Digital (4)
2024 Biotech Beach Standard (1)
2024 Genetown Digital (3)
2024 Genetown Standard (3)
2024 Lone Star Bio Digital (2)
2024 Pharm Country Digital (2)
2024 Pharm Country Standard (2)
2025 BioForest Digital (2)
2025 Lone Star Bio Digital (4)
2026 BioCapital Standard (1)
2026 Biotech Bay Standard (1)
2026 Pharm Country Standard (1)
Academia (441)
Adcomms (6)
Allergies (32)
Alliances (23222)
ALS (36)
Alzheimer's disease (384)
Antibody-drug conjugate (ADC) (35)
Approvals (6327)
Artificial intelligence (102)
Autoimmune disease (7)
Automation (3)
Bankruptcy (149)
Best Places to Work (4381)
BIOSECURE Act (9)
Biosimilars (55)
Biotechnology (40)
Bladder cancer (18)
Brain cancer (15)
Breast cancer (74)
Cancer (574)
Cardiovascular disease (67)
Career advice (408)
Career pathing (12)
CAR-T (20)
Cell therapy (82)
Cervical cancer (4)
Clinical research (30861)
Collaboration (321)
Compensation (131)
Complete response letters (17)
COVID-19 (757)
CRISPR (19)
C-suite (113)
Cystic fibrosis (35)
Data (586)
Denatured (15)
Depression (9)
Diabetes (77)
Diagnostics (1316)
Diversity (2)
Diversity, equity & inclusion (13)
Drug discovery (55)
Drug pricing (63)
Drug shortages (12)
Duchenne muscular dystrophy (33)
Earnings (32051)
Editorial (11)
Employer branding (4)
Employer resources (43)
Events (37377)
Executive appointments (348)
FDA (6677)
Featured Employer (21)
Friedreich's ataxia (2)
Frontotemporal dementia (1)
Funding (203)
Gene editing (37)
Generative AI (8)
Gene therapy (98)
GLP-1 (338)
Government (1285)
Grass and pollen (2)
Guidances (15)
Healthcare (3565)
Huntington's disease (4)
IgA nephropathy (9)
Immunology and inflammation (33)
Indications (12)
Infectious disease (788)
Inflammatory bowel disease (54)
Inflation Reduction Act (6)
Influenza (12)
Intellectual property (43)
Interviews (59)
IPO (5875)
IRA (29)
Job creations (2050)
Job search strategy (373)
Kidney cancer (6)
Labor market (10)
Layoffs (177)
Leadership (3)
Legal (3429)
Liver cancer (19)
Lung cancer (76)
Lymphoma (50)
Machine learning (1)
Management (16)
Manufacturing (141)
MASH (31)
Medical device (1274)
Medtech (1276)
Mergers & acquisitions (9656)
Metabolic disorders (247)
Multiple sclerosis (18)
NASH (14)
Neurodegenerative disease (21)
Neuropsychiatric disorders (6)
Neuroscience (547)
NextGen: Class of 2025 (1586)
Non-profit (594)
Northern California (668)
Now hiring (8)
Obesity (140)
Opinion (119)
Ovarian cancer (21)
Pain (49)
Pancreatic cancer (13)
Parkinson's disease (41)
Partnered (7)
Patents (102)
Patient recruitment (28)
Peanut (10)
People (28860)
Pharmaceutical (65)
Pharmacy benefit managers (11)
Phase I (8032)
Phase II (13057)
Phase III (11718)
Pipeline (381)
Podcasts (47)
Policy (58)
Postmarket research (1401)
Preclinical (3207)
Press Release (25)
Prostate cancer (44)
Psychedelics (9)
Radiopharmaceuticals (120)
Rare diseases (157)
Real estate (2635)
Recruiting (17)
Regulatory (10078)
Reports (14)
Research institute (563)
Resumes & cover letters (55)
Rett syndrome (1)
RNA editing (2)
RSV (6)
Schizophrenia (33)
Series A (35)
Series B (11)
Service/supplier (3)
Sickle cell disease (30)
Southern California (681)
Special edition (6)
Spinal muscular atrophy (77)
Sponsored (6)
Startups (1628)
State (2)
Stomach cancer (3)
Supply chain (28)
The Weekly (29)
United States (6765)
Vaccines (149)
Venture capitalists (13)
Webinars (10)
Weight loss (96)
Women's health (8)
Worklife (3)
Date
Today (44)
Last 7 days (215)
Last 30 days (891)
Last 365 days (12095)
2025 (2906)
2024 (12511)
2023 (14250)
2022 (19567)
2021 (20080)
2020 (19038)
2019 (14891)
2018 (11714)
2017 (13889)
2016 (13130)
2015 (15474)
2014 (12419)
2013 (10592)
2012 (11397)
2011 (11923)
2010 (10889)
Location
Africa (313)
Alabama (13)
Alaska (1)
Arizona (53)
Arkansas (3)
Asia (20083)
Australia (2602)
California (1617)
Canada (867)
China (226)
Colorado (65)
Connecticut (65)
Delaware (52)
Europe (39341)
Florida (299)
Georgia (35)
Idaho (9)
Illinois (181)
India (14)
Indiana (128)
Iowa (1)
Japan (85)
Kansas (55)
Kentucky (12)
Maine (2)
Maryland (245)
Massachusetts (1388)
Michigan (28)
Minnesota (89)
Missouri (23)
Montana (8)
Nebraska (6)
Nevada (7)
New Hampshire (6)
New Jersey (704)
New Mexico (7)
New York (467)
North Carolina (375)
North Dakota (2)
Northern California (668)
Ohio (48)
Oklahoma (4)
Oregon (16)
Pennsylvania (407)
Puerto Rico (8)
Rhode Island (7)
South America (501)
South Carolina (2)
Southern California (681)
Tennessee (34)
Texas (217)
Utah (37)
Virginia (69)
Washington D.C. (29)
Washington State (110)
Wisconsin (14)
265,108 Results for "recursion pharmaceuticals".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Neuroscience
Recursion Reports Thin Mid-Stage Efficacy Data for Rare Brain Disease Therapy
Recursion’s oral drug candidate for cerebral cavernous malformation showed no improvements in patient- or physician-reported outcomes at 12 months. The biotech will engage with the FDA to determine the need for an additional study.
September 4, 2024
·
2 min read
·
Tristan Manalac
Press Releases
Recursion Provides Business Updates and Reports Fourth Quarter and Fiscal Year 2024 Financial Results
March 3, 2025
·
19 min read
Biotech Bay
Helix and Recursion Pharmaceuticals Drive Drug Discovery Innovation Through Clinico-Genomic Data
Helix, a leading population genomics company and provider of precision medicine genomics solutions, announced a groundbreaking multi-year agreement with Recursion Pharmaceuticals, a leading clinical-stage TechBio company decoding biology to industrialize drug discovery.
June 24, 2024
·
2 min read
Press Releases
Angle PLC Announces Agreement with Recursion Pharmaceuticals
September 19, 2024
·
2 min read
Press Releases
Recursion Presents Phase 2 Data for REC-994 in CCM in Late-Breaking Oral Presentation at the International Stroke Conference
February 5, 2025
·
9 min read
Press Releases
Recursion Provides Business Updates and Reports Third Quarter 2024 Financial Results
November 7, 2024
·
17 min read
Business
Recursion Provides Business Updates and Reports First Quarter 2024 Financial Results
Recursion, a leading clinical stage TechBio company decoding biology to industrialize drug discovery, reported business updates and financial results for its first quarter ending March 31, 2024.
May 9, 2024
·
15 min read
Business
Recursion Appoints Najat Khan, PhD, as Chief R&D Officer and Chief Commercial Officer
Recursion announced Najat Khan, PhD, will be its Chief R&D Officer and Chief Commercial Officer.
April 16, 2024
·
5 min read
Business
Recursion Announces Plans to Open New Office in London
Recursion, a leading clinical stage TechBio company decoding biology to industrialize drug discovery, announced plans to open a new office in London’s vibrant King’s Cross neighborhood.
March 11, 2024
·
6 min read
BioMidwest
Recursion and Enamine to Generate and Design Enriched Compound Libraries for Global Drug Discovery Industry
Recursion announced its partnership with Enamine, a world-renowned provider of novel molecules and contract research services, to generate enriched screening libraries with insights from Recursion’s protein-ligand interaction predictions spanning across Enamine’s massive library of 36 billion compounds.
December 20, 2023
·
6 min read
1 of 26,511
Next
